Markus Müschen, MD-PhD, is the Director of the Center of Molecular and Cellular Oncology, Arthur H. and Isabel Bunker Professor of Hematology, and Professor of Immunobiology at Yale University. His research program leverages negative selection mechanisms of the immune system for the treatment of drug-resistant leukemia and lymphoma, the most frequent type of cancer in children and young adults. Over the past 10 years, his laboratory established new conceptual frameworks for the understanding of B-cell signaling and energy metabolism and how these mechanisms are altered in lymphoid malignancies. Influenced by postdoctoral training in immunology (Klaus Rajewsky and Ralf Küppers) and leukemia genetics (Janet D. Rowley), he is particularly interested in signal transduction pathways that affect the clinical trajectory of patients with B-cell leukemia and lymphoma.
To identify potential lymphoid-specific vulnerabilities, the Müschen laboratory has built a bioinformatic target-discovery resource based on mutation and gene expression data from 160 clinical trials, covering 39 cancer types and >25,000 patients. In 2010, Markus Müschen joined the University of California San Francisco (UCSF) as full professor with tenure and served as Program Leader of the Hematological Malignancies Program at the UCSF Comprehensive Cancer Center. Markus Müschen is currently a Howard Hughes Medical Institute (HHMI) Faculty Scholar and my research has been supported by an NCI Outstanding Investigator Award (R35) since 2016. At Yale University, he serves as Director of the Center of Molecular and Cellular Oncology and as mentor for nine junior faculty.
Leveraging mechanisms of B-cell selection to overcome drug-resistance in B-ALL